文献速递妇科生殖医学

FMR1 CGG重复长度与早发性卵巢功能不全风险的大规模分析

Large-scale analysis of FMR1 CGG repeat length and risk of premature ovarian insufficiency in over 92 000 women.
PubMed 文献 · Hum Reprod · 2026-01-01

基于英国生物银行约92 000名女性,分析FMR1 CGG重复长度与早发性卵巢功能不全(POI)的关联。518名前突变携带者中仅6.9%报告POI;重复长度从36次起POI风险升高,但预测能力有限(最大AUC 0.60,多基因评分AUC 0.64)。重复长度与FMR1蛋白水平无关,提示RNA功能获得性毒性机制。

要点

  • FMR1重复长度从36次起与POI风险升高相关,但无强预测阈值。
  • 前突变携带者中POI报告率仅6.9%,挑战FXPOI疾病分类效用。
  • 重复长度与FMR1蛋白水平无关,支持RNA功能获得性毒性机制。

核心结论

  • FMR1重复长度增加POI风险但诊断效用有限,不及更年期时序多基因评分。

研究设计与样本

  • 英国生物银行约92 000名女性横断面分析,具遗传与健康数据。
  • 对女性参与者进行FMR1重复长度基因分型,分析其与自报POI、绝经年龄等生殖表型的关联。
  • 测量FMR1蛋白水平,并进行全基因组分析以识别潜在遗传修饰因子。

主要发现

  • 518名有自然绝经年龄的前突变携带者中,仅6.9%报告POI。
  • POI风险从36次重复开始升高并随重复长度持续增加,但最大AUC仅0.60,多基因评分为0.64。
  • 重复长度与FMR1蛋白水平无关联,符合RNA功能获得性毒性机制。
  • 全基因组分析识别RAD52为潜在遗传修饰因子。

关键数值与推荐

  • 前突变定义为≥55次重复。
  • POI风险升高起始于36次重复。
  • FMR1重复长度预测POI的最大AUC为0.60,多基因评分AUC为0.64。

临床怎么用

  • 临床FMR1前突变检测对POI的预测价值有限,应结合多基因评分等工具综合评估。
  • 关注36次重复以上的风险升高,但不宜单独用于诊断分层。
  • RAD52等遗传修饰因子可能为未来风险分层提供新方向。

局限性

  • POI为自报而非临床确诊。
  • 分析未能评估AGG中断、嵌合体或X染色体失活。
  • 遗传修饰因子需重复验证。
  • findings仅限于单一人群数据集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does FMR1 repeat length confer clinically meaningful predictive value for premature ovarian insufficiency (POI)? SUMMARY ANSWER: FMR1 repeat length increases POI risk from ∼36 repeats onward but has limited diagnostic utility compared with a polygenic score for menopause timing. WHAT IS KNOWN ALREADY: FMR1 premutation carriers (≥55 repeats) are reported to have high risk of Fragile-X Associated Primary Ovarian Insufficiency (FXPOI), but prior studies were small and highly ascertained. STUDY DESIGN, SIZE, DURATION: Cross-sectional analysis of ∼92 000 women from the UK Biobank with genetic and health data. PARTICIPANTS/MATERIALS, SETTING, METHODS: Female UK Biobank participants were genotyped for FMR1 repeat length. Associations with self-reported POI, age at menopause, and other reproductive phenotypes were analysed in women. FMR1 protein levels were measured, and genome-wide analyses were conducted to identify potential genetic modifiers. MAIN RESULTS AND THE ROLE OF CHANCE: Of 518 female premutation carriers with available age at natural menopause, only 6.9% reported POI. Elevated POI risk was observed starting at 36 repeats, increasing continuously with repeat length, but no threshold showed strong predictive power (maximum AUC 0.60 vs AUC 0.64 for polygenic score). No association was found between repeat length and FMR1 protein levels, consistent with an RNA gain-of-function toxicity mechanism. RAD52 was identified as a potential genetic modifier. LARGE SCALE DATA: UK Biobank resource (https://www.ukbiobank.ac.uk). LIMITATIONS, REASONS FOR CAUTION: POI was self-reported rather than clinically confirmed. Analyses could not assess AGG interruptions, mosaicism, or X-inactivation. Genetic modifiers require replication. Findings are limited to a single population dataset. WIDER IMPLICATIONS OF THE FINDINGS: These results challenge the utility of the FXPOI disease category, suggest limited diagnostic value of clinical FMR1 premutation testing for POI, and highlight alternative mechanisms and potential modifiers such as RAD52. STUDY FUNDING/COMPETING INTEREST(S): This work was conducted using the UK Biobank resource (application 9905). This work was funded by the Medical Research Council (unit programs: MC_UU_12015/2, MC_UU_00006/2) and Wellcome (Discovery award 302536/Z/23/Z). The sponsors had no role in the study design, collection, analysis, or interpretation of the data, the writing of the manuscript or the decision to submit it for publication. J.R.B.P. and A.M. have engaged in paid consultancy for Ovartix Ltd. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Morbey EJ, Day FR, Wright DJ, et al. Large-scale analysis of FMR1 CGG repeat length and risk of premature ovarian insufficiency in over 92 000 women. Hum Reprod. 2026. PMID: 42001465. doi:10.1093/humrep/deag061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。